Paige

Computational pathology models are the entire product. The company built its position on deep learning applied to whole slide images for cancer detection support, and has since pursued foundation model scale work in oncology imaging, including a pan cancer detection tool designed to identify both common and rare cancer variants across multiple tissue types. There is no non AI version of the offering.

Positioned as delivering insights to pathologists and oncologists so they arrive more efficiently at precise diagnoses, with the pathologist retaining the diagnostic decision. The prostate product was authorized to support cancer detection rather than to render it, which is the appropriate scoping for software reading slides alongside a specialist. Detailed published description of the review workflow and how confidence is surfaced to the pathologist was not located.

The De Novo authorization pathway required performance evidence reviewed by the FDA and established a new device classification, which is a higher transparency bar than clearing against an existing predicate. Foundation model work in partnership with a major technology company has been described publicly in terms of scale. Model architecture, training data provenance, and current performance figures are not published in detail.

The regulatory record is the substance here: the company was first to obtain FDA authorization for an AI based digital pathology product, and subsequently received Breakthrough Device designation for a pan cancer detection tool, a designation intended to expedite review of technologies addressing unmet need rather than a clearance. Acquisition by a large precision medicine company at a reported 81.25 million dollars is a market validation signal of a particular kind, though a modest figure relative to the company's raised capital, which buyers may read as a comment on standalone commercial traction.

No published PHI or data governance framework was located. Post acquisition, data handling now sits within the acquiring organization's policies rather than an independent posture, which is itself the thing a buyer needs to establish.

No HIPAA or BAA commitment was located. Business associate terms would now be negotiated through the acquiring parent rather than with this company independently.

No SOC 2, ISO 27001, or equivalent attestation was located in the materials reviewed.

Historically the most significant regulatory milestone in computational pathology. The company obtained the first FDA authorization for an AI based digital pathology product via the De Novo pathway for its prostate cancer detection software, creating the device classification that later pathology AI products clear into. It subsequently received Breakthrough Device designation for a pan cancer detection tool spanning common and rare variants across tissue types. Buyers should note the distinction the company itself observes: Breakthrough designation expedites review and is not authorization, so the pan cancer product should not be treated as cleared.

No governance framework or bias evaluation was located. The pertinent question for computational pathology is performance variation across scanner platforms, staining protocols, and laboratory practice, and no published analysis addresses it.

No named laboratory information system integrations or standards support were located. The relevant integration surface for pathology AI is the LIS and slide management platform rather than the EHR, and specifics were not published.

No hosting, tenancy, or data residency terms were located, and deployment arrangements are now subject to the acquiring organization's infrastructure decisions.

No published pricing, and the commercial position has fundamentally changed. The company was acquired in August 2025 for a reported 81.25 million dollars by a precision medicine company that is separately indexed here, with the stated strategic rationale being construction of a large oncology foundation model. Buyers evaluating this technology are now evaluating a component of that parent's portfolio rather than an independent vendor, and should establish how the products are packaged and supported going forward.

Oncology pathology, with authorized depth in prostate cancer detection and stated ambition toward pan cancer coverage across common and rare variants in multiple tissue types, the latter designated but not cleared. Buyers are clinical pathology laboratories and, through the parent, precision oncology programs. This has no provider workflow or hospital clinical surface.